These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2934785)

  • 1. Safety profile of aztreonam in clinical trials.
    Newman TJ; Dreslinski GR; Tadros SS
    Rev Infect Dis; 1985; 7 Suppl 4():S648-55. PubMed ID: 2934785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli.
    Simons WJ; Lee TJ
    Rev Infect Dis; 1985; 7 Suppl 4():S783-8. PubMed ID: 2934786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with aztreonam in four Mediterranean countries.
    Daikos GK
    Rev Infect Dis; 1985; 7 Suppl 4():S831-5. PubMed ID: 2934787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections.
    Swabb EA; Jenkins SA; Muir JG
    Rev Infect Dis; 1985; 7 Suppl 4():S772-7. PubMed ID: 3909336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.
    Breedt J; Teras J; Gardovskis J; Maritz FJ; Vaasna T; Ross DP; Gioud-Paquet M; Dartois N; Ellis-Grosse EJ; Loh E;
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4658-66. PubMed ID: 16251309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
    Henry SA; Bendush CB
    Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical studies of aztreonam in Japan.
    Hara K; Kobayashi H; Nishiura T; Yura J; Saito A
    Rev Infect Dis; 1985; 7 Suppl 4():S810-24. PubMed ID: 3909341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aztreonam in the treatment of serious gram-negative infections in the elderly.
    Deger F; Douchamps J; Freschi E; Thys JP; Nève P; Herchuelz A
    Int J Clin Pharmacol Ther Toxicol; 1988 Jan; 26(1):22-6. PubMed ID: 3403089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A; Steru D; Rosset MA; Carbon C
    Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with aztreonam for treatment of infections in children.
    Stutman HR
    Rev Infect Dis; 1991; 13 Suppl 7():S582-5. PubMed ID: 2068462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of aztreonam therapy for serious infections due to gram-negative bacteria.
    McKellar PP
    Rev Infect Dis; 1985; 7 Suppl 4():S803-9. PubMed ID: 3909340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with aztreonam in Europe: a summary of studies in Belgium, England, Finland, Ireland, the Netherlands, Norway, Portugal, and Sweden.
    Norrby SR
    Rev Infect Dis; 1985; 7 Suppl 4():S836-9. PubMed ID: 2934788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra-abdominal infections.
    Birolini D; Moraes MF; de Souza OS
    Chemotherapy; 1989; 35 Suppl 1():49-57. PubMed ID: 2659290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aztreonam: early clinical studies in New Jersey.
    Johnson ES; Eng RK; Perez EM; Smith LG
    N J Med; 1986 Jan; Spec No():26-9. PubMed ID: 3513061
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of aztreonam in serious gram-negative infections.
    Smith G; Bunney RG; Farrell ID; Wood MJ
    J Antimicrob Chemother; 1988 Feb; 21(2):233-41. PubMed ID: 3283094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with aztreonam in Germany and Austria.
    Stille W; Gillissen J
    Rev Infect Dis; 1985; 7 Suppl 4():S825-30. PubMed ID: 3909342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of low dose aztreonam in the treatment of moderate to severe gram-negative bacterial infections.
    Clergeot A; Steru D; Rosset MA; Carbon C
    J Antimicrob Chemother; 1989 May; 23(5):753-8. PubMed ID: 2759924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of aztreonam and aminoglycoside antibiotics in the treatment of serious infections caused by gram-negative bacilli.
    DeMaria A; Treadwell TL; Saunders CA; Porat R; McCabe WR
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1137-43. PubMed ID: 2679368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corrado ML
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.